JP2021059553A - ポビドンヨードを使用した感冒の治療および予防 - Google Patents
ポビドンヨードを使用した感冒の治療および予防 Download PDFInfo
- Publication number
- JP2021059553A JP2021059553A JP2020201805A JP2020201805A JP2021059553A JP 2021059553 A JP2021059553 A JP 2021059553A JP 2020201805 A JP2020201805 A JP 2020201805A JP 2020201805 A JP2020201805 A JP 2020201805A JP 2021059553 A JP2021059553 A JP 2021059553A
- Authority
- JP
- Japan
- Prior art keywords
- pvp
- cold
- virus
- symptoms
- nasal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 title claims abstract description 270
- 201000009240 nasopharyngitis Diseases 0.000 title claims abstract description 167
- 229920000153 Povidone-iodine Polymers 0.000 title claims description 18
- 229960001621 povidone-iodine Drugs 0.000 title claims description 18
- 238000011282 treatment Methods 0.000 title description 93
- 230000002265 prevention Effects 0.000 title description 20
- 238000000034 method Methods 0.000 claims abstract description 147
- 241000700605 Viruses Species 0.000 claims abstract description 131
- 241000282414 Homo sapiens Species 0.000 claims abstract description 66
- 239000002502 liposome Substances 0.000 claims abstract description 63
- 239000000969 carrier Substances 0.000 claims abstract description 27
- FAAHNQAYWKTLFD-UHFFFAOYSA-N 1-butan-2-ylpyrrolidin-2-one Chemical compound CCC(C)N1CCCC1=O FAAHNQAYWKTLFD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 11
- 208000024891 symptom Diseases 0.000 claims description 125
- 239000000203 mixture Substances 0.000 claims description 74
- 238000009472 formulation Methods 0.000 claims description 70
- 230000000694 effects Effects 0.000 claims description 61
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 20
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 19
- 201000009890 sinusitis Diseases 0.000 claims description 19
- 206010033078 Otitis media Diseases 0.000 claims description 17
- 208000036071 Rhinorrhea Diseases 0.000 claims description 17
- 239000007921 spray Substances 0.000 claims description 17
- 206010006451 bronchitis Diseases 0.000 claims description 16
- 241000709661 Enterovirus Species 0.000 claims description 14
- 230000035899 viability Effects 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 9
- 230000000241 respiratory effect Effects 0.000 claims description 9
- 206010011224 Cough Diseases 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 206010041232 sneezing Diseases 0.000 claims description 8
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 7
- 201000007100 Pharyngitis Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 241000701161 unidentified adenovirus Species 0.000 claims description 7
- 206010061598 Immunodeficiency Diseases 0.000 claims description 6
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 230000007813 immunodeficiency Effects 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 206010019233 Headaches Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 231100000869 headache Toxicity 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 208000030500 lower respiratory tract disease Diseases 0.000 claims description 4
- 206010028735 Nasal congestion Diseases 0.000 claims description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 230000000954 anitussive effect Effects 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 229940124584 antitussives Drugs 0.000 claims description 3
- 239000000850 decongestant Substances 0.000 claims description 3
- 208000035824 paresthesia Diseases 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 241000351643 Metapneumovirus Species 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 241000007181 unidentified human coronavirus Species 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 85
- 229910052740 iodine Inorganic materials 0.000 description 77
- 239000011630 iodine Substances 0.000 description 76
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 75
- 208000015181 infectious disease Diseases 0.000 description 68
- 230000003612 virological effect Effects 0.000 description 47
- 239000000243 solution Substances 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 33
- 230000009467 reduction Effects 0.000 description 32
- 210000003097 mucus Anatomy 0.000 description 26
- 229940079593 drug Drugs 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 231100000419 toxicity Toxicity 0.000 description 20
- 230000001988 toxicity Effects 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 230000000844 anti-bacterial effect Effects 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 210000001331 nose Anatomy 0.000 description 18
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 230000008901 benefit Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 230000002779 inactivation Effects 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000003443 antiviral agent Substances 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 9
- 206010057190 Respiratory tract infections Diseases 0.000 description 8
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 229920001525 carrageenan Polymers 0.000 description 8
- 229940113118 carrageenan Drugs 0.000 description 8
- 239000000679 carrageenan Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000003714 granulocyte Anatomy 0.000 description 8
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 8
- 229960000471 pleconaril Drugs 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 235000010418 carrageenan Nutrition 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000007485 viral shedding Effects 0.000 description 7
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 7
- 241000700584 Simplexvirus Species 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- -1 triiodide ions Chemical class 0.000 description 6
- 102000015728 Mucins Human genes 0.000 description 5
- 108010063954 Mucins Proteins 0.000 description 5
- 206010041925 Staphylococcal infections Diseases 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000001886 ciliary effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000005713 exacerbation Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 208000027744 congestion Diseases 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000013178 mathematical model Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 229940097496 nasal spray Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 239000003860 topical agent Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000011256 aggressive treatment Methods 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 210000000959 ear middle Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 208000037921 secondary disease Diseases 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 241001364929 Havel River virus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 206010061494 Rhinovirus infection Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004240 ciliary body Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 230000007501 viral attachment Effects 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 241000380490 Anguina Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000709698 Coxsackievirus A21 Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 206010065735 Laryngeal inflammation Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010065716 Pharyngeal inflammation Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000012569 microbial contaminant Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本特許明細書において、例えば、第1のおよび第2の、左側のおよび右側の、前方のおよび後方の、最上部のおよび最下部のなどの形容詞は、その形容詞によって記載される特定の相対位置または順序を必ずしも必要とすることなく、一方の要素または方法ステップを別の要素または方法ステップから明確にするために、単独で使用される。「含む(comprises)」、「含む(comprising)」、「含む(includes)」、「含む(including)」という用語または類似の用語は、要素のリストを含む方法、系または装置が、それらの要素のみを含むのではなく、掲載されていない他の要素を含む可能性があるように、非排他的な包含を意味することを意図する。
本発明は、感冒および続発症の治療および予防のための方法であって、すべての場合において、周囲温度における非リポソームPVP−I製剤のヒト被験者の鼻道への適用を用い、PVP−Iの濃度が0.10%w/v以上、2.5%w/v以下である方法を含む。本発明の方法は、かぜの症状の重症度または持続期間を減少させることを含む、感冒のカギとなる臨床的尺度において、かなりの良好な転帰をもたらし、それによって感冒の有効な治療のための方法を構成する。
半世紀近くの研究にもかかわらず、感冒に利用可能な有効な治療または予防法は全く存在しない。感冒は、依然として人類を悩ます最も流行する疾患のままであり、毎年、かなりの罹患率、人的被害、入院、生産性の損失、医療制度の負担およびコストに至り、抗生物質耐性の増加という全世界的危機の一因となっている。本発明は、かぜ症状の減少およびかぜ症状の全般的な持続期間の短縮によって測定されるように、かぜを治療するおよびかぜを予防するのに、実証可能なほど安全および有効である、鼻腔内使用のためのPVP−Iを用いる新規な方法を開示する。
Claims (24)
- ヒト被験者における感冒を治療する方法であって、ヒト被験者の鼻道に、周囲温度で、0.10%w/vより高く約2.5%w/v未満の濃度でポビドンヨード(PVP−I)を含む医薬製剤の有効量を適用することを含み、PVP−Iの少なくとも50%がリポソームまたは他の粒子状担体に結合しておらず、感冒の原因となるまたは原因となる可能性のある因子がウイルスである、方法。
- ヒト被験者の鼻道内のウイルスの活性、生存率または数を減少させる方法であって、ウイルスは感冒の原因となるまたは原因となる可能性のある因子であり、ヒト被験者の鼻道に、周囲温度で、0.10%w/vより高く約2.5%w/v未満の濃度でポビドンヨード(PVP−I)を含む医薬製剤の有効量を適用することを含み、PVP−Iの少なくとも50%がリポソームまたは他の粒子状担体に結合していない、方法。
- ヒト被験者における感冒の症状を軽減する方法であって、ヒト被験者の鼻道に、周囲温度で、0.10%w/vより高く約2.5%w/v未満の濃度でポビドンヨード(PVP−I)を含む医薬製剤の有効量を適用することを含み、PVP−Iの少なくとも50%がリポソームまたは他の粒子状担体に結合しておらず、感冒の原因となるまたは原因となる可能性のある因子がウイルスである、方法。
- ヒト被験者における感冒の持続期間を減少させる方法であって、ヒト被験者の鼻道に、周囲温度で、0.10%w/vより高く約2.5%w/v未満の濃度でポビドンヨード(PVP−I)を含む医薬製剤の有効量を適用することを含み、PVP−Iの少なくとも50%がリポソームまたは他の粒子状担体に結合しておらず、感冒の原因となるまたは原因となる可能性のある因子がウイルスである、方法。
- ヒト被験者における感冒に関連する二次的疾病のリスク、発生率または重症度を減少させる方法であって、二次的疾病が、気管支炎、中耳炎および副鼻腔炎からなる群から選択され、ヒト被験者の鼻道に、周囲温度で、0.10%w/vより高く約2.5%w/v未満の濃度でポビドンヨード(PVP−I)を含む医薬製剤の有効量を適用することを含み、PVP−Iの少なくとも50%がリポソームまたは他の粒子状担体に結合しておらず、感冒の原因となるまたは原因となる可能性のある因子がウイルスである、方法。
- COPD、喘息、肺気腫または嚢胞性線維症に罹患しているヒト被験者、或いは免疫不全症を有する人に関し、かぜに関連する下気道疾病のリスク、発生率または重症度を減少させる方法であって、ヒト被験者の鼻道に、周囲温度で、0.10%w/vより高く約2.5%w/v未満の濃度でポビドンヨード(PVP−I)を含む医薬製剤の有効量を適用することを含み、PVP−Iの少なくとも50%がリポソームまたは他の粒子状担体に結合しておらず、感冒の原因となるまたは原因となる可能性のある因子がウイルスである、方法。
- 感冒の症状を伴うヒト被験者から感染していないヒト被験者への感冒の伝播のリスクを予防するまたは減少させる方法であって、かぜ症状を伴うヒト被験者の鼻道に、周囲温度で、0.10%w/vより高く約2.5%w/v未満の濃度でポビドンヨード(PVP−I)を含む医薬製剤の有効量を適用することを含み、PVP−Iの少なくとも50%がリポソームまたは他の粒子状担体に結合しておらず、感冒の原因となるまたは原因となる可能性のある因子がウイルスである、方法。
- かぜ症状を伴う他者に曝露されたヒト被験者における感冒を回避する方法であって、ヒト被験者の鼻道に、周囲温度で、0.10%w/vより高く約2.5%w/v未満の濃度でポビドンヨード(PVP−I)を含む医薬製剤の有効量を適用することを含み、PVP−Iの少なくとも50%がリポソームまたは他の粒子状担体に結合しておらず、感冒の原因となるまたは原因となる可能性のある因子がウイルスである、方法。
- 鼻道に適用される医薬製剤中のPVP−I濃度が、約0.1%〜約1.0%w/vである、請求項1から8のいずれか一項に記載の方法。
- 鼻道に適用される医薬製剤中のPVP−I濃度が、約0.2%〜約0.5%w/vである、請求項1から9のいずれか一項に記載の方法。
- 鼻道に適用される医薬製剤中のPVP−I濃度が、約0.2%〜約0.45%w/vである、請求項1から10のいずれか一項に記載の方法。
- PVP−Iの少なくとも70%が、リポソームまたは他の粒子状担体に結合していない、請求項1から11のいずれか一項に記載の方法。
- PVP−Iの少なくとも80%が、リポソームまたは他の粒子状担体に結合していない、請求項1から12のいずれか一項に記載の方法。
- PVP−Iの少なくとも90%が、リポソームまたは他の粒子状担体に結合していない、請求項1から13のいずれか一項に記載の方法。
- 医薬製剤が、リポソームを含有しない、請求項1から14のいずれか一項に記載の方法。
- 医薬製剤が、ヒト被験者の鼻孔中に、1日1回〜12回投与される、請求項1から15のいずれか一項に記載の方法。
- 製剤のそれぞれの投与時に、約0.05mL〜約1.0mLの医薬製剤が、ヒト被験者のそれぞれの鼻孔へ投与される、請求項1から16のいずれか一項に記載の方法。
- 感冒の原因となるまたは原因となる可能性のある因子が、ライノウイルス、ヒトコロナウイルス、インフルエンザウイルス、ヒトパラインフルエンザウイルス、ヒト呼吸器合胞体ウイルス、アデノウイルス、ライノウイルス以外のエンテロウイルス、メタニューモウイルスおよびそれらの任意の組合せからなる群から選択される、請求項1から17のいずれか一項に記載の方法。
- 感冒の原因となるまたは原因となる可能性のある因子が、ヒトライノウイルスである、請求項1から18のいずれか一項に記載の方法。
- 感冒症状が、悪寒、頭痛、うずきおよび疼痛、疲労、鼻水、くしゃみ、咳嗽、鼻閉、咽喉痛ならびにそれらの組合せからなる群から選択される、請求項3に記載の方法。
- 医薬製剤が、鼻腔内溶液、点滴剤、スプレー剤、ゲル剤、エアゾール剤および吸入剤からなる群から選択される剤形の形態である、請求項1から20のいずれか一項に記載の方法。
- 医薬製剤が、うっ血除去剤、抗ヒスタミン剤、鎮痛剤、解熱剤、抗炎症剤、ステロイド、鎮咳剤および去痰剤からなる群から選択される少なくとも1種の薬剤をさらに含む、請求項1から21のいずれか一項に記載の方法。
- 医薬製剤が、少なくとも1種の薬学的に許容される賦形剤、添加剤または担体をさらに含む、請求項1から22のいずれか一項に記載の方法。
- 賦形剤、添加剤または担体が、着香剤、甘味剤、着色剤、溶媒、緩衝剤、アルコール、ポリマー、界面活性剤または製剤の経鼻送達、鼻腔内分布、安定性、有効性、許容性、忍容性を最適化するように設計される他の賦形剤もしくは添加剤である、請求項23に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014206143A AU2014206143C1 (en) | 2014-07-23 | Treatment and prevention of the common cold using povidone-iodine | |
AU2014206143 | 2014-07-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017503154A Division JP2017522330A (ja) | 2014-07-23 | 2015-07-06 | ポビドンヨードを使用した感冒の治療および予防 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021059553A true JP2021059553A (ja) | 2021-04-15 |
JP2021059553A5 JP2021059553A5 (ja) | 2021-05-27 |
Family
ID=51794584
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017503154A Pending JP2017522330A (ja) | 2014-07-23 | 2015-07-06 | ポビドンヨードを使用した感冒の治療および予防 |
JP2020201805A Pending JP2021059553A (ja) | 2014-07-23 | 2020-12-04 | ポビドンヨードを使用した感冒の治療および予防 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017503154A Pending JP2017522330A (ja) | 2014-07-23 | 2015-07-06 | ポビドンヨードを使用した感冒の治療および予防 |
Country Status (18)
Country | Link |
---|---|
US (2) | US11000542B2 (ja) |
EP (2) | EP3326635B1 (ja) |
JP (2) | JP2017522330A (ja) |
CN (1) | CN106794198A (ja) |
AU (2) | AU2015292256B2 (ja) |
CA (1) | CA2955982C (ja) |
DK (1) | DK3326635T3 (ja) |
ES (1) | ES2895429T3 (ja) |
HK (1) | HK1249851A1 (ja) |
HR (1) | HRP20211810T1 (ja) |
HU (1) | HUE056533T2 (ja) |
MY (1) | MY189342A (ja) |
NZ (1) | NZ728284A (ja) |
PH (1) | PH12017500135A1 (ja) |
PL (1) | PL3326635T3 (ja) |
PT (1) | PT3326635T (ja) |
SG (2) | SG11201700286XA (ja) |
WO (1) | WO2016011496A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017522330A (ja) | 2014-07-23 | 2017-08-10 | ファイアブリック・ファーマ・ピー・ティー・ワイ.エル・ティー・ディーFirebrick Pharma Pty Ltd | ポビドンヨードを使用した感冒の治療および予防 |
CA3141483A1 (en) * | 2019-06-10 | 2020-11-26 | Firebrick Pharma Limited | Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes |
CN114269354A (zh) * | 2019-08-30 | 2022-04-01 | 3M创新有限公司 | 应用消毒剂组合物进行病毒的传播预防 |
CN113244263A (zh) * | 2020-02-07 | 2021-08-13 | 北京天衡军威医药技术开发有限公司 | 一种用于预防及治疗呼吸道感染性疾病的雾化吸入制剂 |
CN113244262A (zh) * | 2020-02-07 | 2021-08-13 | 北京天衡军威医药技术开发有限公司 | 一种用于预防及治疗呼吸道感染性疾病的吸入粉雾制剂 |
WO2022099182A1 (en) * | 2020-11-09 | 2022-05-12 | Rucker Capital Advisors | Oral rinse, nasal spray and methods for prevention of covid-19 by lowering viral load of covid-19 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030180380A1 (en) * | 2002-03-20 | 2003-09-25 | Hansen Richard L. | Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use |
JP2008520258A (ja) * | 2004-10-13 | 2008-06-19 | ザ プロクター アンド ギャンブル カンパニー | 抗菌組成物を供給するための装置 |
JP2008523066A (ja) * | 2004-12-09 | 2008-07-03 | ザ ダイアル コーポレイション | 高い抗ウイルス効果および抗菌効果を有している組成物 |
JP2012092153A (ja) * | 2003-08-28 | 2012-05-17 | Pure Bioscience | 第2抗菌剤を含むクエン酸二水素銀組成物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3028300A (en) | 1960-09-13 | 1962-04-03 | West Laboratories Inc | Germicidal compositions and methods for preparing the same |
US5038769A (en) | 1983-06-29 | 1991-08-13 | Krauser Robert S | Method and apparatus for treating ailments |
US4523589A (en) * | 1983-06-29 | 1985-06-18 | Krauser Robert S | Method and apparatus for treating ailments |
US6171611B1 (en) | 1997-11-12 | 2001-01-09 | Dante J. Picciano | Iodine-containing nasal moisturizing saline and mouthwash solutions |
JPH11228387A (ja) * | 1998-02-05 | 1999-08-24 | Taisho Pharmaceut Co Ltd | ヨード系殺菌剤を含有する薬用組成物 |
JP4741727B2 (ja) | 1998-05-27 | 2011-08-10 | ユーロ−セルティーク エス.エイ. | 抗炎症剤、特に消毒剤及び/又は創傷治癒促進剤を下気道に適用するための製剤 |
US7297344B1 (en) | 1999-05-27 | 2007-11-20 | Euro-Celtique, S.A. | Preparations for the promotion of wound healing in the upper respiratory tract and/or ear |
US6694041B1 (en) | 2000-10-11 | 2004-02-17 | Digimarc Corporation | Halftone watermarking and related applications |
US8679462B2 (en) | 2002-04-11 | 2014-03-25 | Saeed Rezakhany | Methods of preventing respiratory infections |
JP2004352642A (ja) | 2003-05-29 | 2004-12-16 | Meiji Seika Kaisha Ltd | ウイルス感染症予防剤 |
US20080138438A1 (en) * | 2004-12-09 | 2008-06-12 | The Dial Cprporation | Compositions Having A High Antiviral And Antibacterial Efficacy |
US20060280809A1 (en) | 2005-06-14 | 2006-12-14 | Leshchiner Adele K | Anti-infective iodine based compositions for otic and nasal use |
US8303994B2 (en) | 2006-06-22 | 2012-11-06 | Jack Howard Kessler | Method for the eradication of pathogens including S. aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells |
WO2012177251A1 (en) * | 2011-06-22 | 2012-12-27 | Adeda Therapeutics Company Limited | Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases |
CN103751274B (zh) | 2014-02-20 | 2016-08-17 | 河北旺达饲料兽药开发有限公司 | 一种治疗鸭、鹅黄病毒感染的药物组合物及其制备方法 |
JP2017522330A (ja) | 2014-07-23 | 2017-08-10 | ファイアブリック・ファーマ・ピー・ティー・ワイ.エル・ティー・ディーFirebrick Pharma Pty Ltd | ポビドンヨードを使用した感冒の治療および予防 |
KR20170033925A (ko) | 2015-09-17 | 2017-03-28 | 송경진 | 항바이러스 및 세균용 스프레이 조성물 |
KR101935250B1 (ko) | 2017-07-04 | 2019-01-04 | 김대황 | 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물 |
-
2015
- 2015-07-06 JP JP2017503154A patent/JP2017522330A/ja active Pending
- 2015-07-06 ES ES18152155T patent/ES2895429T3/es active Active
- 2015-07-06 DK DK18152155.0T patent/DK3326635T3/da active
- 2015-07-06 SG SG11201700286XA patent/SG11201700286XA/en unknown
- 2015-07-06 US US15/327,998 patent/US11000542B2/en active Active
- 2015-07-06 PT PT181521550T patent/PT3326635T/pt unknown
- 2015-07-06 SG SG10201900559VA patent/SG10201900559VA/en unknown
- 2015-07-06 HR HRP20211810TT patent/HRP20211810T1/hr unknown
- 2015-07-06 NZ NZ728284A patent/NZ728284A/en unknown
- 2015-07-06 CN CN201580046383.9A patent/CN106794198A/zh active Pending
- 2015-07-06 WO PCT/AU2015/050378 patent/WO2016011496A1/en active Application Filing
- 2015-07-06 EP EP18152155.0A patent/EP3326635B1/en active Active
- 2015-07-06 AU AU2015292256A patent/AU2015292256B2/en active Active
- 2015-07-06 PL PL18152155T patent/PL3326635T3/pl unknown
- 2015-07-06 CA CA2955982A patent/CA2955982C/en active Active
- 2015-07-06 HU HUE18152155A patent/HUE056533T2/hu unknown
- 2015-07-06 MY MYPI2017700171A patent/MY189342A/en unknown
- 2015-07-06 EP EP15824932.6A patent/EP3171881A4/en not_active Withdrawn
-
2017
- 2017-01-20 PH PH12017500135A patent/PH12017500135A1/en unknown
-
2018
- 2018-07-18 HK HK18109282.8A patent/HK1249851A1/zh unknown
-
2019
- 2019-05-01 AU AU2019100465A patent/AU2019100465B4/en not_active Expired
-
2020
- 2020-06-19 US US16/907,086 patent/US20200316109A1/en not_active Abandoned
- 2020-12-04 JP JP2020201805A patent/JP2021059553A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030180380A1 (en) * | 2002-03-20 | 2003-09-25 | Hansen Richard L. | Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use |
JP2012092153A (ja) * | 2003-08-28 | 2012-05-17 | Pure Bioscience | 第2抗菌剤を含むクエン酸二水素銀組成物 |
JP2008520258A (ja) * | 2004-10-13 | 2008-06-19 | ザ プロクター アンド ギャンブル カンパニー | 抗菌組成物を供給するための装置 |
JP2008523066A (ja) * | 2004-12-09 | 2008-07-03 | ザ ダイアル コーポレイション | 高い抗ウイルス効果および抗菌効果を有している組成物 |
Non-Patent Citations (5)
Title |
---|
「うがい薬のイソジン(ポビドンヨード)は、鼻の中の消毒にも使っていいのでしょうか?」−YAHOO!知, JPN6021045133, 17 September 2006 (2006-09-17), JP, ISSN: 0004885641 * |
「明治/イソジンうがい薬(医薬品)の口コミ(BY YOMIさん)|美容・化粧品情報はアットコスメ」、, JPN6021045131, 1 May 2011 (2011-05-01), JP, ISSN: 0004885640 * |
DERMATOLOGY, vol. 204, JPN6019003896, 2002, pages 114 - 120, ISSN: 0004885638 * |
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. Vol. 317, Issue 2, JPN6019003895, 2006, pages 161 - 166, ISSN: 0004885637 * |
川名林治 外: "ポビドンヨード(PVP−1)によるウイルスの不活化に関する研究 −市販の消毒剤との比較", 臨床とウイルス, vol. 26, no. 5, JPN6021045130, 1998, JP, pages 371 - 386, ISSN: 0004885639 * |
Also Published As
Publication number | Publication date |
---|---|
AU2014206143B1 (en) | 2014-10-23 |
SG11201700286XA (en) | 2017-02-27 |
US11000542B2 (en) | 2021-05-11 |
JP2017522330A (ja) | 2017-08-10 |
AU2019100465B4 (en) | 2020-06-18 |
EP3326635A1 (en) | 2018-05-30 |
PT3326635T (pt) | 2021-11-04 |
PH12017500135B1 (en) | 2017-05-29 |
ES2895429T3 (es) | 2022-02-21 |
AU2015292256A1 (en) | 2017-06-15 |
HUE056533T2 (hu) | 2022-02-28 |
PH12017500135A1 (en) | 2017-05-29 |
CN106794198A (zh) | 2017-05-31 |
MY189342A (en) | 2022-02-04 |
EP3326635B1 (en) | 2021-09-01 |
WO2016011496A1 (en) | 2016-01-28 |
HRP20211810T1 (hr) | 2022-03-04 |
AU2015292256B2 (en) | 2020-09-17 |
HK1249851A1 (zh) | 2018-11-16 |
NZ728284A (en) | 2020-07-31 |
CA2955982C (en) | 2023-09-05 |
EP3171881A4 (en) | 2018-01-10 |
DK3326635T3 (da) | 2021-11-15 |
AU2019100465A4 (en) | 2019-06-06 |
SG10201900559VA (en) | 2019-02-27 |
EP3171881A1 (en) | 2017-05-31 |
US20170165296A1 (en) | 2017-06-15 |
PL3326635T3 (pl) | 2022-02-07 |
CA2955982A1 (en) | 2016-01-28 |
US20200316109A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021059553A (ja) | ポビドンヨードを使用した感冒の治療および予防 | |
US20200323843A1 (en) | Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus | |
JP5470047B2 (ja) | 抗ウイルス組成物及び使用方法 | |
JP6419195B2 (ja) | モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療 | |
US20040248825A1 (en) | Use of neuraminidase inhibitors to prevent flu associated bacterial infections | |
WO2017212422A1 (en) | Topical compositions comprising carbomer for the treatment and prevention of viral infections and allergic conditions | |
WO2007001323A2 (en) | Methods and compositions for inhibiting, destroying, and/or inactivating viruses | |
EP3085382A1 (en) | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis | |
WO2011047065A1 (en) | Recombinant human cc10 protein for treatment of influenza | |
WO2021202332A1 (en) | Aqueous formulations containing povidone iodine for effective treatment and prevention of virus infections | |
US20060287364A1 (en) | Methods of prevention of infection with HIV/AIDS, venereal disease and influenza | |
US20220273594A1 (en) | Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections | |
US20090270472A1 (en) | Method to use oxymetazoline to interrupt the development of the common cold syndrome | |
JP2020510703A (ja) | 哺乳類の皮膚および粘膜の単純ヘルペス症状の治療 | |
CN115867288A (zh) | 用于治疗呼吸系统病症的组合物 | |
JP2005281227A (ja) | インフルエンザウイルス感染症の治療および予防薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201228 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220622 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221003 |